Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels

被引:111
作者
Ong, Sena C.
Schoder, Heiko
Patel, Snehal G.
Tabangay-Lim, Ida M.
Doddamane, Indukala
Gonen, Mithat
Shaha, Ashok R.
Tuttle, R. Michael
Shah, Jatin P.
Larson, Steven M.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
F-18-FDG PET; medullary thyroid cancer; calcitonin;
D O I
10.2967/jnumed.106.036681
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Medullary thyroid carcinoma (MTC) is a rare endocrine tumor arising from the C-cells of the thyroid gland. Calcitonin is the principal serum tumor marker. A rising calcitonin level after total thyroidectomy for localized disease generally indicates residual, recurrent, or metastatic disease. The role of F-18-FDG PET in MTC remains somewhat unclear. We reviewed our own experience with F-18-FDG PET in postthyroidectomy MTC patients with elevated calcitonin. Methods: From our database, we identified patients with suspected residual, recurrent, or metastatic MTC and elevated calcitonin who had been referred for F-18-FDG PET between January 2000 and October 2005. F-18-FDG PET findings were classified as positive or negative on the basis of visual interpretation of the scan. Standardized uptake values (SUVs) were also calculated. The F-18-FDG PET-findings were verified by histopathologic examination, when available, or other imaging studies and clinical follow-up. Any negative F-18-FDG PET result was considered false-negative. Results: Twenty-eight patients underwent a total of 38 F-18-FDG PET studies. Calcitonin levels ranged from 106 to 541,000 pg/mL (median, 7,260 pg/mL). There were 23 true-positive, 1 false-positive, and 14 false-negative F-18-FDG PET scans, yielding an overall sensitivity of 62%. There was no true-positive finding when calcitonin levels were below 509 pg/mL (n = 5). Using an arbitrary cutoff of 1,000 pg/mL, we found that the sensitivity in scans with calcitonin levels greater than 1,000 pg/mL increased to 78% (21/27; 95% confidence interval, 58%-91%). The mean SUV of all lesions with 18F-FDG uptake was 5.3 +/- 3.2 (range, 2.0-15.9). Among the 14 patients with false-negative F-18-FDG PET findings, 8 had concurrent anatomic imaging studies and only 2 of these had positive findings. Conclusion: F-18-FDG PET can detect residual, recurrent, or metastatic MTC with a reasonable sensitivity of 78% when the calcitonin level is above 1,000 pg/mL but appears of limited use if the calcitonin level is below 500 pg/mL.
引用
收藏
页码:501 / 507
页数:7
相关论文
共 33 条
[1]   Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin [J].
Adalet, I ;
Koçak, M ;
Oguz, H ;
Alagöl, F ;
Cantez, S .
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (04) :353-359
[2]  
Adams S, 1998, EUR J NUCL MED, V25, P79
[3]   Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma [J].
Bernà, L ;
Chico, A ;
Matías-Guiu, X ;
Mato, E ;
Catafau, A ;
Alonso, C ;
Mora, J ;
Mauricio, D ;
Rodríguez-Espinosa, J ;
Marí, RE ;
Flotats, A ;
Martín, JC ;
Estorch, M ;
Carrió, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (11) :1482-1488
[4]   The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer [J].
Brandt-Mainz, K ;
Müller, SP ;
Görges, R ;
Saller, B ;
Bockisch, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (05) :490-496
[5]  
BUSNARDO B, 1984, CANCER, V53, P278, DOI 10.1002/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO
[6]  
2-Z
[7]   Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer [J].
de Groot, JWB ;
Links, TP ;
Jager, PL ;
Kahraman, T ;
Plukker, JTM .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (08) :786-794
[8]   CALCITONIN AND CARCINOEMBRYONIC ANTIGEN AS TUMOR MARKERS IN MEDULLARY-THYROID CARCINOMA [J].
DELELLIS, RA ;
RULE, AH ;
SPILER, I ;
NATHANSON, L ;
TASHJIAN, AH ;
WOLFE, HJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1978, 70 (04) :587-594
[9]   Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer:: results of a multicentre study [J].
Diehl, M ;
Risse, JH ;
Brandt-Mainz, K ;
Dietlein, M ;
Bohuslavizki, KH ;
Matheja, P ;
Lange, H ;
Bredow, J ;
Körber, C ;
Grünwald, F .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) :1671-1676
[10]  
Erdi YE, 2004, J NUCL MED, V45, P813